Cx43 hemichannel blocker (IC50 ~7 μM). No significant affinity for gap junctions or Panx1 channels. N-terminal transactivator of transcription (TAT) motif promotes membrane permeability and increases inhibitory effect of Gap19 (Cat. No. 5353). Active in vivo. Brain penetrant.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 1 mg/ml in water|
References are publications that support the biological activity of the product.
Abudara et al (2014) The connexin43 mimetic peptide Gap19 inhibits hemichannels without altering gap junctional communication in astrocytes. Front.Cell.Neurosci. 8 1 PMID: 25374505
Freitas-Andrade and Naus (2016) Astrocytes in neuroprotection and neurodegeneration: The role of connexin43 and pannexin1. Neuroscience. 323 207 PMID: 25913636
If you know of a relevant reference for TAT-Gap19, please let us know.
View Related Products by Product Action
Keywords: TAT-Gap19, TAT-Gap19 supplier, Inhibitors, Inhibits, connexin43, Cx43, Brain, penetrant, Cell, permeable, Gap, Channels, 6227, Tocris Bioscience
Citations for TAT-Gap19
Citations are publications that use Tocris products.
Currently there are no citations for TAT-Gap19. Do you know of a great paper that uses TAT-Gap19 from Tocris? Please let us know.
Reviews for TAT-Gap19
There are currently no reviews for this product. Be the first to review TAT-Gap19 and earn rewards!
Have you used TAT-Gap19?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.